Humanized antibodies with increased stability
US12227569B2 · kind B2 · utility
0Cited by
14References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 15, 2021 |
| Grant date | Feb 18, 2025 |
| Priority date | — |
| Expiry date | Sep 24, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.